Topic resource collection
Approved comparison material connected to this topic.
83 resourcesRead both sides
Best Research Peptides vs Prescription Peptides Guide 2026 Discover how research peptides vs prescription peptides differ in 2026. Compare regulatory status, quality standards, and compounding options. Learn more. Reviewed by Bra…
Before interpreting this table, understand that peptide research for gut permeability exists primarily in preclinical models and Phase 1–2 human trials. No peptide discussed here has completed Phase 3 FDA approval specifically fo…
MOTS-C operates through the mitochondrial genome. Not the nuclear genome. Binding directly to mitochondrial ribosomes to upregulate genes controlling oxidative phosphorylation and fatty acid metabolism. A 2021 study in Cell Metab…
True senolytic peptides. Compounds that selectively induce apoptosis in senescent cells without affecting proliferating or quiescent cells. Remain largely theoretical. The most validated senolytics are small molecules: dasatinib …
Thymosin Alpha-1 T-regulatory cell upregulation, Treg/Th17 rebalancing Direct (restores immune tolerance) Indirect (reduces ongoing damage) Minimal direct effect Phase 2 human trials in autoimmune thyroiditis BPC-157 VEGF/FGF-2 u…
Research peptides for gut restoration fall into two mechanistic categories that operate through distinct biological pathways. Epithelial repair peptides. BPC-157, TB-500 (Thymosin Beta-4), and GHK-Cu. Upregulate growth factors (V…
BPC-157 Angiogenesis and mucosal repair VEGF receptor activation, nitric oxide signaling 10 mcg/kg–10 mg/kg daily Moderate. Multiple animal studies, no human RCTs Best studied for structural repair; oral bioavailability contested…
Before selecting peptides for hepatic steatosis research, understanding the distinct mechanisms, dosing requirements, and measurable endpoints for each compound prevents protocol design errors that waste research time and funding…
BPC-157 VEGF/PDGF upregulation for angiogenesis and oligodendrocyte support eNOS activation, reduced oxidative stress Subcutaneous or oral (15% bioavailability orally) 40–60% reduction in demyelination severity Strongest preclini…
MOTS-C Mitochondrial transcription upregulation, increases ATP synthesis 30–40% Cell Metabolism 2021: improved glucose uptake 35%, reduced lactate during exertion Yes. Mitochondrial adaptations persist 8+ weeks after dosing stops…
Before you begin. This table compares mechanism, target site, and research application for each peptide. The 'Professional Assessment' column addresses when each peptide is most appropriate and when it's not. SS-31 (Elamipretide)…
GLP-1 Agonists (Semaglutide) GLP-1 receptor activation → delayed gastric emptying, reduced appetite Fasting glucose, triglycerides, waist circumference 0.25–2.4mg weekly SC Subcutaneous injection Gold standard for multi-component…
NMN (Nicotinamide Mononucleotide) NAD+ precursor; bypasses NAMPT rate-limiting step Metabolic senescence; CD38-driven NAD+ depletion 100–500 μM (in vitro); 250–500 mg/kg (in vivo) High. Multiple RCTs, published in Science, Cell M…
Epitalon Telomerase activation via pineal-hypothalamic signaling 0.5–10 μg/g body weight Subcutaneous or intraperitoneal injection 16–33% increase in telomerase activity over 10–20 passages (human fibroblasts, Oncotarget 2019) Tr…
BPC-157 Mast cell stabilisation, VEGF/FGF upregulation Prevents histamine/cytokine release; repairs gut and BBB permeability 40–60% reduction in mast cell activation markers (neuroinflammation models, 2021) 200–500mcg daily subcu…
The following table compares the primary research peptides studied for visceral adipose tissue reduction across mechanism, administration, and documented outcomes. CJC-1295 (with DAC) GHRH receptor agonist; stimulates endogenous …
BPC-157 Enhances fibroblast migration; upregulates VEGF for angiogenesis 200–500 mcg daily Subcutaneous or intramuscular Days 3–5 through week 6 Best for accelerating collagen deposition during proliferative phase TB-500 Promotes…
CJC-1295 (DAC) GHRH analog. Stimulates pituitary GH release, elevates hepatic IGF-1 production, activates mTOR signaling 6–8 days 100mcg 2x/week subcutaneous Serum IGF-1 AUC, lean body mass (DEXA), muscle CSA (MRI) Gold standard …
GHK-Cu ECM remodeling, VEGF upregulation Lysyl oxidase, TGF-β pathway 0.05–0.2% topical daily 30 days (2–8°C, light-protected) Phase II clinical data; 285% follicle enlargement in vitro TB-500 Anti-inflammatory, stem cell migrati…
GHK-Cu (Copper Peptide) Upregulates collagen I/III synthesis via TGF-β signaling; modulates MMP-1/2 activity to reduce collagen degradation Microneedling (0.5–1.5mm depth) with 0.05–0.1% solution applied immediately post-treatmen…